Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2017, No. 6


Ontiveros‑Sánchez de la Barquera JA
Respuesta a antidepresivos serotoninérgicos y noradrenérgicos: estudio cruzado con fluoxetina y desipramina en pacientes con un primer episodio depresivo mayor
Gac Med Mex 2017; 153 (6)

Idioma: Español
Referencias bibliográficas: 31
Paginas: 688-694
Archivo PDF: 219.00 Kb.


Texto completo




RESUMEN

Antecedentes: Las tasas de respuesta a diferentes clases de antidepresivos ayudan a elaborar guías para la prescripción racional en farmacoterapia. Sin embargo, existen pocos estudios comparativos con antidepresivos inhibidores selectivos de la recaptación de serotonina o noradrenalina en la misma muestra de pacientes con depresión mayor. Método: Pacientes ambulatorios con un primer episodio depresivo mayor (DSM-III-R) que completaron 6 semanas de tratamiento en dos estudios a doble ciego aleatorizados con fluoxetina y desipramina que recibieron por 6 semanas de manera cruzada el otro fármaco antidepresivo. Como respuesta se consideró si el puntaje final de la escala Hamilton de depresión disminuyó un 50% o más desde la determinación basal. Resultados: No encontramos diferencias por tratamiento o secuencia. Diez de los 18 pacientes (55.5%) respondieron a fluoxetina y desipramina, tres(16.6%) fueron resistentes para fluoxetina y tres (16.6%) para Desipramina, y dos (11.1%) para ambos fármacos. Discusión: Nuestro estudio sugiere que, en pacientes ambulatorios con un primer episodio depresivo, la fluoxetina y la desipramina son igualmente eficaces. En los pacientes que no respondieron a uno de los fármacos estudiados, el otro tratamiento fue eficaz; esta maniobra de tratamiento debe ser considerada en estos pacientes.


Palabras clave: Fluoxetina, Desipramina, Depresión mayor, Primer episodio, Estudio cruzado.


REFERENCIAS

  1. Green AI, Schatzberg AF. Obituary. Joseph J. Schildkraut, 1934-2006. Neuropsychopharmacology. 2007;32:1855-6.

  2. Schildkraut, JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122:509-22.

  3. Goldstein DJ, Potter WZ, Ciraulo DA, et al. Biological theories of depression and implications for current and new treatments. En: Ciraulo DA, Shader RI, editores. Pharmacotherapy of depression. 2nd ed. New York: Human Press; 2011. p. 1-32.

  4. Humble M. Noradrenaline and serotonin reuptake inhibition as clinical principle: a review of antidepressant efficacy. Acta Psychiatr Scand. 2000;101(Suppl 402):28-36.

  5. Riddle MA, Scahill L, King RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolsc Psychiatr. 1992;31:1062-9.

  6. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990;47:577-85.

  7. Hollander E, Allen A, Kwon J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder. Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56:1033-9.

  8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd edition-revisited. Washington, DC: American Psychiatric Press; 1987.

  9. Äberg-Wisted A, Jostell KG, Ross SB, et al. Effects of zimelidine and desipramine on serotinin and noradrenaline uptake mechanism in relation to plasma concentrations and to therapeutic effects during treatment of depression. Psychopharmacology. 1981;74:297-305.

  10. Äberg-Wistedt A. A double blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. I. Clinical finding. Acta Psychiatr Scand. 1982;66:50-65.

  11. Äberg-Wistedt A. Comparison between zimelidine and desipramine in endogenous depression. A cross-over study. Acta Psychiatr Scand. 1982;66:129-38.

  12. Lingjaerde O, Bratfos O, Bratlid T, et al. A double-blind comparison of zimelidine and desipramine in endogenous depression. Acta Psychiatr Scand. 1983;68:22-33.

  13. Nystgröm C, Hällström T. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. A cross-over study. Acta Psychiatr Scand. 1987;75:377-82.

  14. Äberg A. Controlled crossover study of a 5HT uptake inhibiting and an NA uptake inhibiting antidepressant. Acta Psychiatr Scand. 1981;63(Suppl 190):224-55.

  15. van Praag HM. New evidence of serotonin-deficient depressions. Neuropsychobiology. 1977;3:56-63.

  16. Burns RA, Lock T, Edwards DR, et al. Predictors of response to amine- specific antidepressants. J Affect Disord. 1995;35:97-106.

  17. Potter WZ, Calil HM, Extein I, et al. Specific norepinephrine and serotonin uptake inhibitors in man: a crossover study with pharmacokinetic, biochemical, neuroendocrine and behavioral parameters. Acta Psychiatr Scand Suppl. 1981;290:152-65.

  18. Nyström C, Hällström T. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. A cross-over study. Acta Psychiatr Scand. 1987;75:377-82.

  19. White K, Wykoff W, Tyness LL, et al. Fluovoxamine in the treatment of tricyclic-resistant depression. J Psychatr Neurosci. 1990;15:156-8.

  20. Szegedi A, Wetzel H, Angersbach D, et al. A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry. 1997;30 97-105.

  21. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand. 1988;78:668-75.

  22. Emrich H, Berger M, Riemann D, et al. Serotonin reuptake inhibition versus norepinephrine reuptake inhibition: a double-blind differential therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatrica. 1987;20:60-3.

  23. Thase ME, Rush AJ. Treatment-resistant depression. En: Bloom FE, Kupfer DJ, editors. Psychopharmacology, the fourth generation of progress. New York: Raven Press; 1995. p. 1081-97.

  24. Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol. 1993; 135:305‑11.

  25. Delgado PL, Price LH, Charney DS, et al. Efficacy of fluovoxamine in treatment-refractory depression. J Affect Disord. 1988;15 55-60.

  26. Souery D, Serretti A, Calati R, et al. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies. A randomized open study. World J Biol Psych. 2011;12 364-73.

  27. Papakostas GI, Fava M. Pharmacotherapy for depression and treatment-resistant depression. USA: World Scientific Publishing Co. Pte. Ltd; 2010.

  28. Nierenberg AA, Papakostas GI, Petersen T, et al. Nortriptyline for treatment- resistant depression. J Clin Psychiatry. 2003;64 35-9.

  29. Suckow RF, Roose SP, Cooper TB. Effect of fluoxetine on plasma desipramine and 2-hidroxydesipramine. Biol Psychiatry. 1992;31(2 Suppl): 200-4.

  30. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14(2 Suppl): 90-8.

  31. Van Ameringen M, Mancini C. Adverse effects of switching from fluoxetine to desipramine (letter). Can J Psychiatry. 1992;37(4 Suppl):278.



>Revistas >Gaceta Médica de México >Año2017, No. 6
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019